Tag Archives: Treatment

Are Osteoarthritis Patients Receiving The Correct Treatment?

Research has found that physicians who treat osteoarthritis patients are usually not using standard treatment guidelines which are based on the latest medical evidence. The researchers noted medical practitioners were prescribing medications for inflammation and pain, or choosing surgical interventions instead of suggesting weight loss or exercise plans to patients with osteoarthritis.[1] A 2002 World… Read More »

FDA Approves Fiasp (insulin aspart injection) for the Treatment of Children with Diabetes

Print this page PLAINSBORO, N.J., Jan. 6, 2020 /PRNewswire/ — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with diabetes.1 Fiasp is the first and only fast-acting mealtime insulin injection that does not… Read More »

FDA Approves Beovu (brolucizumab-dbll) for the Treatment of Wet Age-Related Macular Degeneration (AMD)

FDA Approves Beovu (brolucizumab-dbll) for the Treatment of Wet Age-Related Macular Degeneration (AMD) Print this page EAST HANOVER, N.J., Oct. 8, 2019 /PRNewswire/ — Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Beovu (brolucizumab-dbll) injection, also known as RTH258, for the treatment of wet age-related macular degeneration (AMD)1. Beovu is the… Read More »

FDA Approves Reyvow (lasmiditan), the First Serotonin (5-HT) 1F Receptor Agonist for the Acute Treatment for Migraine

FDA Approves Reyvow (lasmiditan), the First Serotonin (5-HT) 1F Receptor Agonist for the Acute Treatment for Migraine Print this page INDIANAPOLIS, Oct. 11, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Reyvow (lasmiditan) an oral medication for the acute treatment of migraine,… Read More »